MHRA and FDA release Joint Paper on Data Integrity in Clinical Trials
Recommendation
28/29 April 2026
From QbD to Process Validation
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
MHRA and FDA GCP Inspectors have released a joint paper on data integrity in global clinical trials. The paper is published in the Journal of Clinical Pharmacology and Therapeutics.
How to ensure data Integrity in clinical trials
Concerns with data reliability could lead to rejection of data used in submissions, but it can also pose significant safety risks, the agencies say.
According to the MHRA, the joint paper describes
- the need for robust processes to manage data,
- issues that impact data integrity, such as audit trails, maintaining the study blind and general data management practices,
- case studies where MHRA and FDA have raised concerns during GCP inspections.
In addition, the agencies are working towards a programme of collaborative and joint inspections.
The MHRA notes that a further joint paper with the FDA is expected to be released in the near future. The second publication will discuss topics like sponsor oversight, electronic source documents, protocol deviations and data quality in novel clinical trial designs.
More information can be found on MHRA´s Blog entitled MHRA and FDA Joint Paper 'Data Integrity in Global Clinical Trials'.
Related GMP News
04.02.2026When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
27.01.2026New Ph. Eur. Publication Schedule
21.01.2026EU Pharma Package: EMA with single Point of Information
14.01.2026European QP Association Developments September through December 2025
14.01.2026Could a change of ownership be relevant to GMP?
07.01.2026Is QP Certification required when Products do not enter EU Territory?